Please note that this product was withdrawn from the Union Register of orphan medicinal products in May 2020 on request of the sponsor.
On 22 February 2018, orphan designation (EU/3/18/1981) was granted by the European Commission to Midatech Pharma Plc, United Kingdom, for mertansine functionalised gold nanoconjugate for the treatment of hepatocellular carcinoma.
The sponsorship was transferred to Midatech Pharma Espana Sociedad Limitada in November 2019.
Mertansine functionalised gold nanoconjugate
|Disease / condition||
Treatment of hepatocellular carcinoma
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.